MIRA Pharmaceuticals, Inc. Common Stock Cash Flow Conversion Efficiency
MIRA Pharmaceuticals, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has a cash flow conversion efficiency ratio of -0.148x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.21 Million) by net assets ($8.16 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of MIRA Pharmaceuticals, Inc. Common Stock (2020–2025)
Cash flow conversion efficiency of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2025. This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View MIRA Pharmaceuticals, Inc. Common Stock stock price for real-time trading data and today's change.
MIRA Pharmaceuticals, Inc. Common Stock Cash Flow Conversion Ratio Explained
MIRA Pharmaceuticals, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MIRA Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see MIRA stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Maat Pharma SA
PA:MAAT
|
-1.853x |
|
First Au Ltd
AU:FAU
|
-0.443x |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
-0.063x |
|
First Graphene Ltd
AU:FGR
|
-0.220x |
|
Petratherm Ltd
AU:PTR
|
-0.044x |
|
Jasa Kita Bhd
KLSE:8648
|
-0.020x |
|
Bonava AB (publ)
ST:BONAV-A
|
-0.022x |
|
Rifa Ind
KO:000760
|
0.011x |
Annual Cash Flow Conversion Efficiency for MIRA Pharmaceuticals, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2025. Review MIRA free cash flow debt coverage to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $10.39 Million | $-4.66 Million | -0.449x | +82.25% |
| 2024-12-31 | $2.20 Million | $-5.56 Million | -2.528x | -143.97% |
| 2023-12-31 | $4.37 Million | $-4.53 Million | -1.036x | -111.02% |
| 2022-12-31 | $-596.23K | $-5.60 Million | 9.400x | +1644.70% |
| 2021-12-31 | $2.26 Million | $-1.38 Million | -0.609x | -160.86% |
| 2020-12-31 | $-67.99K | $-67.99K | 1.000x | -- |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical mar… Read more